Results 11 to 20 of about 148,764 (203)

EFFECTS OF CERTAIN DRUGS ON DIHYDROPYRIMIDINE DEHYDROGENASE ENZYME PURIFIED FROM BOVINE LIVER [PDF]

Slovenian Veterinary Research, 2017
The inhibitory effects of certain drugs on dihydropyrimidine dehydrogenase from the bovine liver have been investigated. Dihydropyrimidine dehydrogenase [5, 6-dihydrouracil: NADP+ oxidoreductase, EC 1.3.1.2; DPD] enzyme was purified from the bovine ...
Imdat Aygul, Hasan Ozdemir, Mehmet Ciftci   +2 more
doaj   +4 more sources

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity [PDF]

Case Reports in Oncological Medicine, 2016
Over the past decades, 5-Fluorouracil (5-FU) has been widely used to treat several types of carcinoma, including esophageal squamous cell carcinoma. In addition to its common side effects, including diarrhea, mucositis, neutropenia, and anemia, 5-FU ...
Keiki Nagaharu, Kenji Ikemura, Yoshiki Yamashita, Hiroyasu Oda, Mikiya Ishihara, Yumiko Sugawara, Satoshi Tamaru, Toshiro Mizuno, Naoyuki Katayama   +8 more
doaj   +2 more sources

Relationship Between Dihydropyrimidine Dehydrogenase Gene Polymorphism and Toxicities in Cancer Patients Receiving 5-Fluorouracil [PDF]

Forbes Tıp Dergisi
Objective: Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme that degrades uracil, thymine, and 5-fluorouracil, which are important for treating gastric, colorectal, and breast cancers.
Tahsin YÜKSEL, Çiğdem CİNDOĞLU
doaj   +3 more sources

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. [PDF]

ESMO Open, 2023
BACKGROUND: The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European Medicines Agency (EMA) recommended two methods for pre-treatment DPD deficiency testing
de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiadèr CR, ‘The Working Group on the Implementation of DPD-deficiency Testing in Europe’.   +9 more
europepmc   +4 more sources

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity [PDF]

Autopsy and Case Reports, 2018
5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its ...
Shiraz S. Fidai, Aarti E. Sharma, Daniel N. Johnson, Jeremy P. Segal, Ricardo R. Lastra   +4 more
doaj   +2 more sources

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD). [PDF]

Int J Mol Sci
Pre-treatment genotyping of four well-characterized toxicity risk-variants in the dihydropyrimidine dehydrogenase gene (DPYD) has been widely implemented in Europe to prevent serious adverse effects in cancer patients treated with fluoropyrimidines ...
Ambrodji A, Sadlon A, Amstutz U, Hoch D, Berger MD, Bastian S, Offer SM, Largiadèr CR.   +7 more
europepmc   +3 more sources

The dihydropyrimidine dehydrogenase gene contributes to heritable differences in sleep in mice [PDF]

Current Biology, 2021
Raymond Galante, Gary Churchill, Allan I Pack   +2 more
exaly   +2 more sources

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD). [PDF]

Elife
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance.
Zhang T, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiadèr CR, Offer SM.   +13 more
europepmc   +3 more sources

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity [PDF]

, 2023
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are associated with decreased dihydropyrimidine dehydrogenase activity.
de Vos-Geelen, J., Ockeloen, Charlotte W., Ockeloen, Charlotte W, Bosch, B.J. van den, Coenen, Marieke JH, de Vos-Geelen, Judith, Bierau, J., Ockeloen, C.W., Coenen, Marieke J.H., van den Bosch, Bianca JC, Willemsen, A.E.C.A.B., Bierau, Jörgen, Hijmans-van der Vegt, Manon, Willemsen, Annelieke ECAB, Raaijmakers, Aron, Willemsen, Annelieke E.C.A.B., van den Bosch, B.J.C., van den Bosch, Bianca J.C., Raaijmakers, A., Vos-Geelen, J. de, Hijmans-van der Vegt, M., Coenen, M.J.H.   +21 more
core   +3 more sources

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen? [PDF]

J Adv Pract Oncol, 2020
5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening.
Vogel WH, Minhas A, Baumrucker S.
europepmc   +2 more sources